|
| |
BioPortfolio's Approved Drugs DatabaseHepseraAdefovir DipivoxilDownload PDF containing detailed information.
Press Releases About Hepsera:
|
 |
| China's Hepatitis B Virus Drug Market Will Grow to $800 Million by 2012 |
28th August, 2008 |
Decision Resources |
WALTHAM, Mass., Aug. 28 /PRNewswire/ -- Decision Resources, one of the
world's leading research and advisory firms focusing on pharmaceutical and
healthcare issues, finds that the Chinese
|
| Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS) |
8th July, 2008 |
Pharmasset, Inc. |
PRINCETON, N.J., July 8 /PRNewswire-FirstCall/ -- The French National
Agency for Research on AIDS and Viral Hepatitis (ANRS), with the support of
Pharmasset, Inc. (Nasdaq: VRUS) and Gilead
|
| Chronic viral hepatitis: B is for billions |
1st March, 2005 |
Datamonitor |
Chronic viral hepatitis: B is for
billions
Despite
recent advances in the treatment and management of hepatitis B, the market is
still relatively immature, with several key unmet needs.
|
| Chronic hepatitis B and C: a chronic lack of effective treatment |
1st January, 1970 |
Datamonitor |
Chronic hepatitis B / C:
a chronic lack of effective treatment
The World Health Organization estimates that
one-third of the entire world's population has been exposed to hepatitis B (HBV)
|
This page has been viewed 21 times
Browse BioPortfolio's InDepth service - alphabetically:
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
or by Most Publications, recently searched for, or
most viewed.
Search for Hepsera across BioPortfolio, or for Hepsera Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH.
Thumbshots from Thumbshots.org
|